https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-showcases-novel-nampt-inhibitor-during-podium-presentation-at-the-42nd-annual-j.p.-morgan-healthcare-conference 2025-12-29 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-to-present-results-from-phase-1-healthy-volunteer-study-of-nampt-inhibitor-rpt1g-and-other-progress-at-the-67th-american-society-of-hematology-(ash)-annual-meeting-and-exposition 2026-02-16 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-advances-rpt1g-for-myeloid-cancer-patients-with-phase-1-safety-data-and-ind-approval 2026-03-25 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-raises-%2418-million-financing-to-accelerate-advancement-of-lead-asset-rpt1g-into-phase-1%2F2-trials 2026-02-16 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-to-showcase-novel-nampt-inhibitor-during-oral-presentation-at-2023-american-society-of-hematology-(ash)-annual-meeting 2026-02-16 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-initiates-dosing-in-phase-1-clinical-trial-of-rpt1g%2C-a-first-in-class-hyperbolic-nampt-inhibitor 2026-02-16 https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-announces-presentation-at-the-66th-american-society-of-hematology-(ash)-annual-meeting 2025-12-29 https://www.remedyplan.com/press-releases-1/update-remedy-plan-therapeutics-showcases-preclinical-data-from-first-in-class-nampt-inhibitor%2C-rpt1g%2C-demonstrating-synergy-with-bcl-2-family-inhibitors-in-aml-at-the-2024-ash-annual-meeting 2026-02-16